Filana Therapeutics to Participate in the 2026 Maxim Growth Summit

Filana Therapeutics (FLNA) management will participate in the 2026 Maxim Growth Summit, held October 12–14, 2026, in New York.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Filana Therapeutics (FLNA) management will participate in the 2026 Maxim Growth Summit, held October 12–14, 2026, in New York. The conference format is one-on-one meetings, and the venue is The Hard Rock Hotel NYC.

Key Terms

tuberous sclerosis complex

1 terms

tuberous sclerosis complex medical

"treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy"

Tuberous sclerosis complex is a genetic disorder that causes noncancerous growths to form in multiple organs such as the brain, kidneys, heart and lungs, often leading to seizures, developmental delays and organ problems. Investors watch it because treatments, diagnostics and devices targeting this condition can drive clinical trial activity, regulatory decisions and long-term healthcare costs; think of it like a design flaw in a building blueprint that creates many small structural issues needing medical solutions and funding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

10/09/2026 - 08:00 AM

AUSTIN, Texas, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the Company’s management team will participate in the 2026 Maxim Growth Summit being held October 12-14, 2026 in New York.

2026 Maxim Growth Summit Conference Details:

Format: One-on-one meetings
Date: October 12–14, 2026
Location: The Hard Rock Hotel NYC

For more information and a complete agenda, please visit www.maximgrp.com/2026-growth-summit.

About Filana Therapeutics, Inc.

Filana Therapeutics, Inc. (NASDAQ: FLNA), is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A.

For more information, please visit: https://www.FilanaTx.com

For More Information Contact:
Investors
Mike Moyer
mmoyer@lifesciadvisors.com

Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
ESchoen@FilanaTx.com
IR@FilanaTx.com